A Phase 3 interventional study of BXCL501 and Matching Placebo in Agitation and Dementia, sponsored by BioXcel Therapeutics Inc. Terminated at 7 sites in United States. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.
Sponsored by BioXcel Therapeutics Inc · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,050 studies in Dementia with a site in United States — 212 open to participants now, 277 under way, 15 of them phase 3. Dementia · United States.
Among the 1,050 studies in Dementia with a site in United States, this one is the 766th largest by enrollment of the 846 interventional ones that give a count, is one of 88 that started in 2022, is one of 58 in phase 3, and was the 776th registered.
2,375 studies on the registry are indexed under Dementia; 574 are open to participants now.
Browse Dementia studies →212 of the 1,050 studies in Dementia with a site in United States are open now. Recruiting first, the newest first:
University of Nebraska · Sites in United States
Ages 50+ · Women only · Healthy volunteers
University of Pittsburgh · Sites in United States
Ages 65+
The University of Texas Medical Branch, Galveston · Sites in United States
Ages 50–100 · Healthy volunteers
Weill Medical College of Cornell University · Sites in United States
Ages 21+ · Healthy volunteers
The Cleveland Clinic · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 383 Dementia studies recruiting now, 244 (64%) set no upper age limit and 25 (7%) stop at 75 or younger; 16 take children under 18; 164 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,050 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 73 · Phase 2 146 · Phase 3 79 · Phase 4 33
First in 1981; this study’s year is marked. 88 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 13 is below the median of 90 across 1,761 interventional studies indexed under Dementia.
Median enrollment 94 across the 846 interventional studies, 200 across the 199 observational. Of the 714 that completed or were terminated, 309 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
191 of 1,050 have an industry lead sponsor. The 10 most frequent:
BioXcel Therapeutics Inc is the lead sponsor of 15 studies on the registry; 1 is open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 9 (75%) have results posted.
BioXcel Therapeutics Inc has 4 studies filed under Dementia — fewer than ten, so there is no comparison to draw.
109 of the studies in Dementia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05543681IGC Pharma, LLCClinical Trial on Agitation in Alzheimer's Dementia | 2026-11 |
| NCT07430371Rendever, Inc.Virtual Reality for Caregiver Assembly, Relief, Empowerment, and Support (VR-CARES) | 2026-11 |
| NCT06095284Virginia Commonwealth UniversityPrescribing Trends and Associated Outcomes of Antiepileptic Drugs in US Nursing Homes Surrounding the COVID-19 Pandemic | 2026-11-30 |
| NCT06298474Hopeful AgingThe BRAIN App (Phase 2 SBIR) | 2026-11-30 |
| NCT07859865Drexel UniversityMindfulness-based Movement Therapy for Persons With Dementia and Family Caregivers | 2026-11-30 |
Add all 109 to your calendar (.ics) → With an account.
Among the 1,050 studies in Dementia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A study to determine the safety and efficacy of BXCL501 dosing for episodes of agitation associated with dementia when they occur (given as needed [PRN]), for a maximum of 168 doses within a 12-week treatment period.
A randomized, double-blind, placebo-controlled, parallel group, 3-arm study assessing efficacy, safety, and tolerability of two doses of BXCL501 in male and female participants (65 years and older) with acute psychomotor agitation associated with dementia.
Approximately 150 participants will participate in this study. Participants will receive a single film consisting of BXCL501 40 micrograms (µg) dose or BXCL501 60 µg dose or placebo. Participants must reside in a care facility where all study-related procedures and study drug dosing will be performed.
2,375 studies on the registry are indexed under Dementia; 574 are open to participants now.
This study's enrollment of 13 is below the median of 90 across 1,761 interventional studies indexed under Dementia.
Browse Dementia studies →BioXcel Therapeutics Inc is the lead sponsor of 15 studies on the registry; 1 is open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 9 (75%) have results posted.
Compared within Dementia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Psychomotor Agitation. The counts are of registry records indexed under each term, refreshed daily. How we classify →
The criteria were revised on the registry on Oct 1, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive 40 μg of BXCL501 sublingually or buccally, with up to 2 doses permitted per calendar day over the 12-week treatment period.
Drug: BXCL501
Participants will receive 60 μg of BXCL501 sublingually or buccally, with up to 2 doses permitted per calendar day over the 12-week treatment period.
Drug: BXCL501
Participants will receive placebo-matched to BXCL501 with up to 2 doses permitted per calendar day over the 12-week treatment period.
Drug: Matching Placebo
Solid-dose film administered sublingually or buccally
Also known as: Dexmedetomidine
Matching solid-dose film administered sublingually or buccally
Change From Pre-dose in PEC Total Score at 30 Minutes Post-dose for the First Treated Episode of Agitation
The PEC includes 5 items-poor impulse control, tension, hostility, uncooperativeness, and excitement-each of which is rated from 1 (minimum) to 7 (maximum); the sum of these 5 items the PEC total score, ranges from 5 (absence of agitation) to 35 (extremely severe). Lower score indicated better outcome.
Time frame: Pre-dose, 30 minutes post-dose
Change From Pre-dose in PEC Total Score at 1 Hour Post-dose for the First Treated Episode of Agitation
The PEC includes 5 items-poor impulse control, tension, hostility, uncooperativeness, and excitement-each of which is rated from 1 (minimum) to 7 (maximum); the sum of these 5 items, the PEC total score ranges from 5 (absence of agitation) to 35 (extremely severe). Lower score indicated better outcome.
Time frame: Pre-dose, 1 hour post-dose
Change From Pre-dose in PEC Total Score at 2 Hours Post-dose for the First Treated Episode of Agitation
The PEC includes 5 items-poor impulse control, tension, hostility, uncooperativeness, and excitement-each of which is rated from 1 (minimum) to 7 (maximum); the sum of these 5 items, the PEC total score ranges from 5 (absence of agitation) to 35 (extremely severe). Lower score indicated better outcome.
Time frame: Pre-dose, 2 hours post-dose
Change From Pre-dose in PEC Total Score at 4 Hours Post-dose for the First Treated Episode of Agitation
The PEC includes 5 items-poor impulse control, tension, hostility, uncooperativeness, and excitement-each of which is rated from 1 (minimum) to 7 (maximum); the sum of these 5 items, the PEC total score ranges from 5 (absence of agitation) to 35 (extremely severe). Lower score indicated better outcome.
Time frame: Pre-dose, 4 hours post-dose
Change From Pre-dose in PEC Total Score at 8 Hours Post-dose for the First Treated Episode of Agitation
The PEC includes 5 items-poor impulse control, tension, hostility, uncooperativeness, and excitement-each of which is rated from 1 (minimum) to 7 (maximum); the sum of these 5 items, the PEC total score ranges from 5 (absence of agitation) to 35 (extremely severe). Lower score indicated better outcome.
Time frame: Pre-dose, 8 hours post-dose
Change From Pre-dose in PEC Total Score at 12 Hours Post-dose for the First Treated Episode of Agitation
The PEC includes 5 items-poor impulse control, tension, hostility, uncooperativeness, and excitement-each of which is rated from 1 (minimum) to 7 (maximum); the sum of these 5 items, the PEC total score ranges from 5 (absence of agitation) to 35 (extremely severe). Lower score indicated better outcome.
Time frame: Pre-dose, 12 hours post-dose
Change From Pre-dose in PEC Total Score at 24 Hours Post-dose for the First Treated Episode of Agitation
The PEC includes 5 items-poor impulse control, tension, hostility, uncooperativeness, and excitement-each of which is rated from 1 (minimum) to 7 (maximum); the sum of these 5 items, the PEC total score ranges from 5 (absence of agitation) to 35 (extremely severe). Lower score indicated better outcome.
Time frame: Pre-dose, 24 hours post-dose
Change From Pre-dose in Pittsburgh Agitation Scale (PAS) Total Score at 2 Hours Post-dose for the First Episode of Agitation
The PAS is an instrument based on direct observations of the participant that is developed to monitor the severity of agitation associated with dementia. The PAS is the sum of 4 behavior groups observed (aberrant vocalization, motor agitation, aggressiveness, resisting care, each behavior group ranging from 0 \[not present\] to 4 \[maximally present\]), and thus total score ranges from 0 (absence of agitation) to 16 (extremely severe). Lower score indicated better outcome.
Time frame: Pre-dose, 2 hours post-dose
Change From Pre-dose in Clinical Global Impression of Severity (CGI-S) Score at 2 Hours Post-dose for the First Episode of Agitation
The CGI-S was used to rate the severity of agitation. The score ranges from 0 to 4 that comprises of, 0=not assessed; 1=normal, not at all symptomatic; 2=mildly symptomatic-low level of symptoms-little interference in social functioning; 3=moderately symptomatic-some prominent symptoms-some interference in functioning; 4=severely symptomatic- very marked symptoms make it difficult for participants to engage with others. Higher scores indicate greater severity of agitation.
Time frame: Pre-dose, 2 hours post-dose
Clinical Global Impression of Improvement (CGI-I) Score at 30 Minutes, 1 Hour, and 2 Hours Post-dose for the First Treated Episodes of Agitation
The CGI-I is a global measure of improvement or change from baseline in participant's condition. The CGI-I score ranges from 0 to 7 that comprises of 0 = not assessed (missing), 1= very much improved, 2= much improved, 3= minimally improved, 4= no change, 5= minimally worse, 6= much worse, and 7= very much worse. Higher scores indicate worse condition.
Time frame: 30 minutes, 1 hour, and 2 hours post-dose
Change From Pre-dose in Agitation-Calmness Evaluation Scale (ACES) Scores at 1, 2, 4, and 8 Hours Post-dose for the First Episode of Agitation.
The ACES is a single-item clinician-rated measure of agitation and sedation. Scores range from 1 to 9, where 1= marked agitation, 2= moderate agitation, 3= mild agitation, 4= normal behavior, 5= mild calmness, 6= moderate calmness, 7= marked calmness, 8= deep sleep, and 9= unarousable. Higher scores indicate greater levels of calmness and sedation.
Time frame: Pre-dose, 1, 2 , 4 and 8 hours post-dose
Number of Treated Episodes of Agitation After the First Treated Episode
Time frame: Up to 12 weeks
The study was conducted in United States from 05-Dec-2022 to 11-Sep-2023.
| Milestone | BXCL501: 40 μg | BXCL501: 60 μg | Placebo |
|---|---|---|---|
| Started | 5 | 3 | 5 |
| Completed | 4 | 3 | 5 |
| Not completed | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 |
The PEC includes 5 items-poor impulse control, tension, hostility, uncooperativeness, and excitement-each of which is rated from 1 (minimum) to 7 (maximum); the sum of these 5 items the PEC total score, ranges from 5 (absence of agitation) to 35 (extremely severe). Lower score indicated better outcome.
| score on a scale | BXCL501: 40 μg | BXCL501: 60 μg | Placebo |
|---|---|---|---|
| Change From Pre-dose in PEC Total Score at 30 Minutes Post-dose for the First Treated Episode of Agitation | -4.2 ± 2.28 | -3.0 ± 0.00 | -6.8 ± 5.81 |
The PEC includes 5 items-poor impulse control, tension, hostility, uncooperativeness, and excitement-each of which is rated from 1 (minimum) to 7 (maximum); the sum of these 5 items, the PEC total score ranges from 5 (absence of agitation) to 35 (extremely severe). Lower score indicated better outcome.
| score on a scale | BXCL501: 40 μg | BXCL501: 60 μg | Placebo |
|---|---|---|---|
| Change From Pre-dose in PEC Total Score at 1 Hour Post-dose for the First Treated Episode of Agitation | -6.4 ± 2.07 | -5.7 ± 1.53 | -6.0 ± 5.79 |
The PEC includes 5 items-poor impulse control, tension, hostility, uncooperativeness, and excitement-each of which is rated from 1 (minimum) to 7 (maximum); the sum of these 5 items, the PEC total score ranges from 5 (absence of agitation) to 35 (extremely severe). Lower score indicated better outcome.
| score on a scale | BXCL501: 40 μg | BXCL501: 60 μg | Placebo |
|---|---|---|---|
| Change From Pre-dose in PEC Total Score at 2 Hours Post-dose for the First Treated Episode of Agitation | -4.4 ± 5.13 | -3.3 ± 3.51 | -5.2 ± 8.56 |
The PEC includes 5 items-poor impulse control, tension, hostility, uncooperativeness, and excitement-each of which is rated from 1 (minimum) to 7 (maximum); the sum of these 5 items, the PEC total score ranges from 5 (absence of agitation) to 35 (extremely severe). Lower score indicated better outcome.
| score on a scale | BXCL501: 40 μg | BXCL501: 60 μg | Placebo |
|---|---|---|---|
| Change From Pre-dose in PEC Total Score at 4 Hours Post-dose for the First Treated Episode of Agitation | -12.0 | -11.0 | -15.3 ± 2.31 |
The PEC includes 5 items-poor impulse control, tension, hostility, uncooperativeness, and excitement-each of which is rated from 1 (minimum) to 7 (maximum); the sum of these 5 items, the PEC total score ranges from 5 (absence of agitation) to 35 (extremely severe). Lower score indicated better outcome.
| score on a scale | BXCL501: 40 μg | BXCL501: 60 μg | Placebo |
|---|---|---|---|
| Change From Pre-dose in PEC Total Score at 8 Hours Post-dose for the First Treated Episode of Agitation | -20.0 | — | -12.0 |
The PEC includes 5 items-poor impulse control, tension, hostility, uncooperativeness, and excitement-each of which is rated from 1 (minimum) to 7 (maximum); the sum of these 5 items, the PEC total score ranges from 5 (absence of agitation) to 35 (extremely severe). Lower score indicated better outcome.
No measurements were reported for this outcome.
The PEC includes 5 items-poor impulse control, tension, hostility, uncooperativeness, and excitement-each of which is rated from 1 (minimum) to 7 (maximum); the sum of these 5 items, the PEC total score ranges from 5 (absence of agitation) to 35 (extremely severe). Lower score indicated better outcome.
| score on a scale | BXCL501: 40 μg | BXCL501: 60 μg | Placebo |
|---|---|---|---|
| Change From Pre-dose in PEC Total Score at 24 Hours Post-dose for the First Treated Episode of Agitation | -12.0 | -5.0 | -8.5 ± 7.78 |
The PAS is an instrument based on direct observations of the participant that is developed to monitor the severity of agitation associated with dementia. The PAS is the sum of 4 behavior groups observed (aberrant vocalization, motor agitation, aggressiveness, resisting care, each behavior group ranging from 0 \[not present\] to 4 \[maximally present\]), and thus total score ranges from 0 (absence of agitation) to 16 (extremely severe). Lower score indicated better outcome.
| score on a scale | BXCL501: 40 μg | BXCL501: 60 μg | Placebo |
|---|---|---|---|
| Change From Pre-dose in Pittsburgh Agitation Scale (PAS) Total Score at 2 Hours Post-dose for the First Episode of Agitation | -3.2 ± 2.28 | -2.3 ± 1.15 | -3.0 ± 4.24 |
The CGI-S was used to rate the severity of agitation. The score ranges from 0 to 4 that comprises of, 0=not assessed; 1=normal, not at all symptomatic; 2=mildly symptomatic-low level of symptoms-little interference in social functioning; 3=moderately symptomatic-some prominent symptoms-some interference in functioning; 4=severely symptomatic- very marked symptoms make it difficult for participants to engage with others. Higher scores indicate greater severity of agitation.
| score on a scale | BXCL501: 40 μg | BXCL501: 60 μg | Placebo |
|---|---|---|---|
| Change From Pre-dose in Clinical Global Impression of Severity (CGI-S) Score at 2 Hours Post-dose for the First Episode of Agitation | -0.8 ± 0.84 | -0.3 ± 0.58 | -0.6 ± 1.14 |
The CGI-I is a global measure of improvement or change from baseline in participant's condition. The CGI-I score ranges from 0 to 7 that comprises of 0 = not assessed (missing), 1= very much improved, 2= much improved, 3= minimally improved, 4= no change, 5= minimally worse, 6= much worse, and 7= very much worse. Higher scores indicate worse condition.
| score on a scale | BXCL501: 40 μg | BXCL501: 60 μg | Placebo |
|---|---|---|---|
| 30 min Post-dose | 2.6 ± 0.55 | 3.3 ± 0.58 | 2.2 ± 1.10 |
| 1 hour Post-dose | 2.0 ± 0.00 | 2.3 ± 0.58 | 2.6 ± 2.07 |
| 2 hours Post-dose | 2.8 ± 0.84 | 3.0 ± 1.00 | 3.0 ± 2.35 |
The ACES is a single-item clinician-rated measure of agitation and sedation. Scores range from 1 to 9, where 1= marked agitation, 2= moderate agitation, 3= mild agitation, 4= normal behavior, 5= mild calmness, 6= moderate calmness, 7= marked calmness, 8= deep sleep, and 9= unarousable. Higher scores indicate greater levels of calmness and sedation.
| score on a scale | BXCL501: 40 μg | BXCL501: 60 μg | Placebo |
|---|---|---|---|
| Change at 1 hour Post-dose | 0.6 ± 0.55 | 0.7 ± 0.58 | 1.0 ± 1.22 |
| Change at 2 hours Post-dose | 0.6 ± 0.89 | 0.3 ± 0.58 | 0.8 ± 1.48 |
| Change at 4 hours Post-dose | 2.0 | 2.0 | 2.3 ± 0.58 |
| Change at 8 hours Post-dose | 7.0 | — | 2.0 |
| Number of agitation episodes | BXCL501: 40 μg | BXCL501: 60 μg | Placebo |
|---|---|---|---|
| Number of Treated Episodes of Agitation After the First Treated Episode | 57 | 58 | 59 |
Collected over From first dose of study drug up to 30 days after the last dose (maximum duration:16 weeks). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BXCL501: 40 μg | 0/5 (0%) | 0/5 (0%) | 2/5 (40%) |
| BXCL501: 60 μg | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Placebo | 0/5 (0%) | 1/5 (20%) | 4/5 (80%) |
| Event | BXCL501: 40 μg | BXCL501: 60 μg | Placebo |
|---|---|---|---|
| AgitationPsychiatric disorders | 0/5 | 1/3 | 0/5 |
| PneumoniaInfections and infestations | 0/5 | 0/3 | 1/5 |
| Event | BXCL501: 40 μg | BXCL501: 60 μg | Placebo |
|---|---|---|---|
| BradycardiaCardiac disorders | 2/5 | 0/3 | 0/5 |
| Gait disturbanceGeneral disorders | 0/5 | 1/3 | 0/5 |
| OedemaGeneral disorders | 0/5 | 1/3 | 0/5 |
| DysphoniaRespiratory, thoracic and mediastinal disorders | 0/5 | 1/3 | 0/5 |
| FallInjury, poisoning and procedural complications | 0/5 | 0/3 | 1/5 |
| Abdominal painGastrointestinal disorders | 0/5 | 0/3 | 1/5 |
| Skin irritationSkin and subcutaneous tissue disorders | 0/5 | 0/3 | 1/5 |
| DiarrhoeaGastrointestinal disorders | 0/5 | 0/3 | 1/5 |
| Upper respiratory tract infectionInfections and infestations | 0/5 | 0/3 | 1/5 |
| CellulitisInfections and infestations | 0/5 | 0/3 | 1/5 |
Safety Population: All participants who received at least 1 dose of study drug, with participants classified according to the drug actually received.
| Age, Continuous(years) | BXCL501: 40 μg | BXCL501: 60 μg | Placebo | Total |
|---|---|---|---|---|
| Mean | 84.6 ± 4.83 | 89.3 ± 3.51 | 82.4 ± 8.73 | 84.8 ± 6.54 |
| Sex: Female, Male(Participants) | BXCL501: 40 μg | BXCL501: 60 μg | Placebo | Total |
|---|---|---|---|---|
| Female | 4 | 3 | 2 | 9 |
| Male | 1 | 0 | 3 | 4 |
| Ethnicity (NIH/OMB)(Participants) | BXCL501: 40 μg | BXCL501: 60 μg | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 0 | 1 |
| Not Hispanic or Latino | 5 | 2 | 5 | 12 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | BXCL501: 40 μg | BXCL501: 60 μg | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 5 | 3 | 5 | 13 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Positive and Negative Syndrome Scale - Excited Component (PEC) Total Score at Pre-dose(score on a scale) | BXCL501: 40 μg | BXCL501: 60 μg | Placebo | Total |
|---|---|---|---|---|
| Mean | 19.4 ± 3.91 | 23.0 ± 8.19 | 20.6 ± 1.52 | 20.7 ± 4.37 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2022 to primary completion in Sep 2023, 9 months.
Results were first posted in Oct 2026, 3 years after primary completion. A results delay was requested in Dec 2023.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexmedetomidine
BioXcel Therapeutics Inc